Simon L (@snupsnus) 's Twitter Profile
Simon L

@snupsnus

Interested in the HealthCare Biotech/Pharma industry! #aging too. Occasional math(s) . Not investment advice etc etc

ID: 1132875708

calendar_today30-01-2013 04:00:04

28,28K Tweet

1,1K Followers

1,1K Following

Roy Friedman (@dewdiligence) 's Twitter Profile Photo

Brad Loncar Regardless of whether one agrees with your statement above, the FDA is plainly functioning. Not so long ago, some people on my X stream asserted that the FDA was doomed.

Simon L (@snupsnus) 's Twitter Profile Photo

The US VP tweeting about the "reproducibility crisis" CRISIS more like it-wouldn't have been on my Bingo card for 2025 a few years ago!

Simon L (@snupsnus) 's Twitter Profile Photo

By how much would a quarter more us patients increase clincial trial costs- surely the US patients are most expensive with everything healthcare related super expensive!

pharma bro (@fakepharmabro) 's Twitter Profile Photo

$RGLS / $NVS July 2024: First contact 1/10: Met at JPM 4/4: Offered $3 + $1.5 CVR 4/16: Offered $3.5 + $3.5 CVR 4/20: Offered $6 + $6 CVR 4/23: Offered $6.5 + $6.5 CVR 4/27: Offered $6 + $6 CVR 4/28: Best and final offer $7 + $7 CVR sec.gov/Archives/edgar…

BowTiedBiotech 🧪🔬🧬 (@bowtiedbiotech) 's Twitter Profile Photo

Oh no - we thought Danon was a done deal for approval. Huge blow to Rocket with potential read through to all AAV9 programs? Will there be a path forward with a different immuno-suppressive agent? $RCKT -60% Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of

Oh no - we thought Danon was a done deal for approval.   Huge blow to Rocket with potential read through to all AAV9 programs?  Will there be a path forward with a different immuno-suppressive agent?

$RCKT -60%

Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of
Simon L (@snupsnus) 's Twitter Profile Photo

Same way I feel we have established that injecting stemcells (without some extra secret souce at least) just won't magical cure diseases yet it geht's tried over an over...

Simon L (@snupsnus) 's Twitter Profile Photo

Do you guys also get the same commercial all over and over again like it's groundhog Day... Until you block the weirdos and their strange promotions... Funny that this is a running business and all

Simon L (@snupsnus) 's Twitter Profile Photo

Astra's success from the "Sick man of Pharma" in 2013 to hitting the improbable forecasts in their takeover defense against Pfizer to their remarkable R&D success has been simply stunning- Soriots Astra or Lechleitners Lilly who would you rate higher 2013-2025?

Simon L (@snupsnus) 's Twitter Profile Photo

Grok in the replies sees shoplifting happening here -hopefully they don't roll it out for crime video analysis too soon!

Simon L (@snupsnus) 's Twitter Profile Photo

That's funny X because I dreamt that Glass wouldn't do the right thing (not to proohetic) and then an internet movement shamed them into changing their advice!

Simon L (@snupsnus) 's Twitter Profile Photo

Seems like I missed a lot today $REGN $SNY drop due to itepekimab? That's a drawdown you don't see often in large caps?

Simon L (@snupsnus) 's Twitter Profile Photo

Such a list (of mice strain and their respective properties) would be sooo valuable and useful- why has no one written it yet!

Persimmon Tree Investments (@persimmonti) 's Twitter Profile Photo

$XBI — $BMY Anecdotal, but thought this comment interesting by Boerner about the new FDA: “We’re able to get in-person meetings for the first time in a number of years there.” .

$XBI — $BMY

Anecdotal, but thought this comment interesting by Boerner about the new FDA:

“We’re able to get in-person meetings for the first time in a number of years there.” 

.